NewLimit is a biotechnology company working to radically extend human healthspan. We're developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Co-Founder

Brian Armstrong

Co-Founder

Greg Johnson

Co-Founder

Jacob Kimmel

President

Michael Polansky

Browse more venture capital transactions:

Prev: 5/7/2025: PAQ Therapeutics venture capital transaction
Next: 5/7/2025: Circula venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary